{"prompt": "['NCT03249376', 'Study ID: ITI-007-404', 'Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the', 'Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive', 'Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) Conducted Globally', 'Protocol Amendment Version 1.3 Date: November 5, 2018']['A Phase 3, Randomized, Double-Blind, Placebo-', 'Controlled, Multi-Center Study to Assess the Efficacy', 'and Safety of Lumateperone Monotherapy in the', 'Treatment of Patients with Major Depressive Episodes', 'Associated with Bipolar I or Bipolar II Disorder', '(Bipolar Depression) Conducted Globally', 'ITI-007-404', 'IND# 126,701', 'EUDRA CT# 2017-002317-58', 'Sponsor: Intra-Cellular Therapies, Inc. (ITI)', 'Amendment Version 1.3', 'November 5, 2018', 'STATEMENT OF COMPLIANCE', 'The study will be conducted in accordance with the International Conference on', 'Harmonisation guidelines for Good Clinical Practice (ICH E6) and the Code of Federal', 'Regulations on the Protection of Human Subjects (45 CFR Part 46).', 'CONFIDENTIAL', 'All financial and nonfinancial support for this study will be provided by Intra-Cellular', 'Therapies, Inc. (ITI or ITCI). The concepts and information contained in this document', 'or generated during the study are considered proprietary and may not be disclosed in', 'whole or in part without the expressed, written consent of ITI.', 'Intra-Cellular Therapies, Inc. Confidential', 'i', 'ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Protocol Approval - Sponsor Signatory', 'Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center', 'Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the', 'Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or', 'Bipolar II Disorder (Bipolar Depression) Conducted Globally', 'Protocol Number: ITI-007-404', 'Intra-Cellular Therapies, Inc. Confidential', 'ii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}